Home › Companies › ROYALTY PHARMA PLC › 2023-2024

ROYALTY PHARMA PLC 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ROYALTY PHARMA PLC’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.

18Reported items
405Asset managers
7,362Fund votes
2024-06-06Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROYALTY PHARMA PLC in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ROYALTY PHARMA PLC

These tallies are ROYALTY PHARMA PLC’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROYALTY PHARMA PLC — official shareholder meeting results, meeting held 2024-06-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Pablo Legorreta	469,574,048	16,360,957	91,560	--	24,764,077	Majority: yes
Elect Director: Henry Fernandez	467,493,605	18,441,850	91,110	--	24,764,077	Majority: yes
Elect Director: Bonnie Bassler, Ph.D.	480,331,728	5,609,040	85,797	--	24,764,077	Majority: yes
Elect Director: Errol De Souza, Ph.D.	468,014,051	17,919,666	92,848	--	24,764,077	Majority: yes
Elect Director: Catherine Engelbert	482,164,279	3,725,318	136,968	--	24,764,077	Majority: yes
Elect Director: David Hodgson	474,265,799	11,668,945	91,821	--	24,764,077	Majority: yes
Elect Director: Ted Love, M.D.	457,219,827	28,488,315	318,423	--	24,764,077	Majority: yes
Elect Director: Gregory Norden	472,819,630	13,114,794	92,141	--	24,764,077	Majority: yes
Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers:	448,091,225	37,716,521	218,819	--	24,764,077	Majority: yes
Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm:	510,538,774	175,866	76,002	--	--	Majority: yes
Proposal 6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts:	448,684,306	37,116,575	225,684	--	24,764,077	Majority: yes
There were no broker non-votes on this proposal. Proposal 8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor:	485,875,260	100,511	50,794	--	24,764,077	Majority: yes
Proposal 9. To authorize the Board of Directors to allot shares:	474,984,226	10,910,963	131,376	--	24,764,077	Majority: yes
Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption:	455,564,249	30,278,595	183,721	--	24,764,077	Majority: yes

Source: ROYALTY PHARMA PLC, Form 8-K — read the filing on EDGAR.

How asset managers voted at the ROYALTY PHARMA PLC 2023-2024 meeting

Each item below shows how the 405 asset managers that disclosed a ROYALTY PHARMA PLC vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ROYALTY PHARMA PLC’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. A non-binding advisory vote to approve executive compensation.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 12 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 448,091,225AGAINST: 37,716,521

ROYALTY PHARMA PLC’s own tally for this item (“Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers:”): 448,091,225 for, 37,716,521 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 404 asset managers below cast 85% of the shares they voted on this item FOR (280,835,107 for, 49,098,213 against).

FOR 85%AGAINST 15%

FOR: 280,835,107 (85.1%)AGAINST: 49,098,213 (14.9%)ABSTAIN: 58,421 (0.0%)NOT VOTED: 2,027 (0.0%)UNKNOWN: 163 (0.0%)

Largest asset managers voting on “A non-binding advisory vote to approve executive compensation.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Fidelity	64,355,088	0	0	For
Morgan Stanley	46,732,842	0	0	For
Vanguard	39,154,115	0	0	For
BlackRock	20,140,803	3,847	0	For
VIKING GLOBAL INVESTORS LP	11,543,720	0	0	For
JPMorgan	231	11,521,229	0	Against
ADAGE CAPITAL PARTNERS GP, L.L.C.	10,816,931	0	0	For
Swedbank Robur Fonder AB	0	8,383,000	0	Against
Putnam	0	8,153,586	0	Against
State Street	7,982,558	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	6,552,228	0	0	For
BAILLIE GIFFORD & CO LTD	4,199,306	0	0	For
BAILLIE GIFFORD OVERSEAS LTD	3,592,717	61,873	0	For
Charles Schwab	3,615,518	0	0	For
Transamerica	2,882,812	8,007	0	For
Northern Trust	2,776,137	0	0	For
John Hancock	2,660,280	102,975	0	For
Amundi	267,860	1,920,425	0	Against
GENERAL ATLANTIC, L.P.	2,055,039	0	0	For
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	0	2,014,933	0	Against
NEW SOUTH CAPITAL MANAGEMENT INC	1,922,447	0	0	For
HOMESTEAD ADVISERS CORP	1,892,540	0	0	For
GMT CAPITAL CORP	0	1,884,988	0	Against
Janus Henderson	1,882,289	0	0	For
Brighthouse	1,856,011	1	16,248	For

Showing the 25 largest of 404 asset managers. See all 404 in the interactive database.

2. Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containing the directors' remuneration policy) for the fiscal year ended December 31, 2023

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 448,684,306AGAINST: 37,116,575

ROYALTY PHARMA PLC’s own tally for this item (“Proposal 6. To approve, on a non-binding advisory basis, the Company's U.K. directors' remuneration report in the U.K. Annual Report and Accounts:”): 448,684,306 for, 37,116,575 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 190 asset managers below cast 84% of the shares they voted on this item FOR (124,636,345 for, 23,336,649 against).

FOR 84%AGAINST 16%

FOR: 124,636,345 (84.2%)AGAINST: 23,336,649 (15.8%)ABSTAIN: 58,421 (0.0%)UNKNOWN: 163 (0.0%)

Largest asset managers voting on “Approve on a non-binding advisory basis our U.K. directors' remuneration report (other than the part containin” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
JPMorgan	231	11,521,229	0	Against
Putnam	0	7,017,976	0	Against
BlackRock	5,728,038	0	0	For
BAILLIE GIFFORD & CO LTD	4,199,306	0	0	For
BAILLIE GIFFORD OVERSEAS LTD	3,592,717	61,873	0	For
Transamerica	2,882,812	8,007	0	For
Northern Trust	2,776,137	0	0	For
NEW SOUTH CAPITAL MANAGEMENT INC	1,922,447	0	0	For
GMT CAPITAL CORP	0	1,884,988	0	Against
Brighthouse	1,856,011	1	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	939,910	0	0	For
Jackson National	302,978	561,708	0	Against
Desjardins Global Asset Management Inc.	838,767	0	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
RAYMOND JAMES & ASSOCIATES	0	736,307	0	Against
Eaton Vance	689,870	0	0	For
APG Asset Management US Inc.	649,173	0	0	For

Showing the 25 largest of 190 asset managers. See all 190 in the interactive database.

3. Approve our U.K. directors' remuneration policy.

COMPENSATIONCORPORATE GOVERNANCE

Combines 6 wordings of this item as funds reported it.

87% fund support · no official result

FOR 87%13%

The 100 asset managers below cast 87% of the shares they voted on this item FOR (106,121,903 for, 15,359,761 against).

FOR: 106,121,903 (87.3%)AGAINST: 15,359,761 (12.6%)ABSTAIN: 16,248 (0.0%)

Largest asset managers voting on “Approve our U.K. directors' remuneration policy.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	0	7,017,976	0	Against
BlackRock	5,728,038	0	0	For
JPMorgan	0	4,785,936	0	Against
Transamerica	2,882,812	8,007	0	For
Brighthouse	1,856,011	1	16,248	For
Charles Schwab	0	1,773,729	0	Against
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	302,978	561,708	0	Against
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Against
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 100 asset managers. See all 100 in the interactive database.

4. Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory auditor.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 485,875,260AGAINST: 100,511

ROYALTY PHARMA PLC’s own tally for this item (“There were no broker non-votes on this proposal. Proposal 8. To authorize the Board of Directors to determine the remuneration of the Company's U.K. statutory auditor:”): 485,875,260 for, 100,511 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 99 asset managers below cast 99.9% of the shares they voted on this item FOR (121,460,024 for, 12,998 against).

FOR 99.9%

FOR: 121,460,024 (100.0%)AGAINST: 12,998 (0.0%)ABSTAIN: 18,537 (0.0%)

Largest asset managers voting on “Authorize the Board to determine the remuneration of Ernst & Young in its capacity as our U.K. statutory audit” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

5. Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 510,538,774AGAINST: 175,866

ROYALTY PHARMA PLC’s own tally for this item (“Proposal 3. To ratify the appointment of Ernst & Young LLP, as the Company's independent registered public accounting firm:”): 510,538,774 for, 175,866 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 99 asset managers below cast 99.9% of the shares they voted on this item FOR (121,612,986 for, 12,998 against).

FOR 99.9%

FOR: 121,612,986 (100.0%)AGAINST: 12,998 (0.0%)ABSTAIN: 18,537 (0.0%)

Largest asset managers voting on “Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

6. Election of Directors: Bonnie Bassler , Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 8 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 480,331,728AGAINST: 5,609,040

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Bonnie Bassler, Ph.D.”): 480,331,728 for, 5,609,040 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 99.9% of the shares they voted on this item FOR (121,435,773 for, 13,261 against).

FOR 99.9%

FOR: 121,435,773 (100.0%)AGAINST: 13,261 (0.0%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “Election of Directors: Bonnie Bassler , Ph.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

7. Election of Directors: Catherine Engelbert

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 482,164,279AGAINST: 3,725,318

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Catherine Engelbert”): 482,164,279 for, 3,725,318 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 99.6% of the shares they voted on this item FOR (121,015,178 for, 385,403 against).

FOR 99.6%

FOR: 121,015,178 (99.6%)AGAINST: 385,403 (0.3%)ABSTAIN: 93,799 (0.1%)

Largest asset managers voting on “Election of Directors: Catherine Engelbert” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

8. Election of Directors: David Hodgson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 474,265,799AGAINST: 11,668,945

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: David Hodgson”): 474,265,799 for, 11,668,945 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 99.6% of the shares they voted on this item FOR (121,050,633 for, 398,401 against).

FOR 99.6%

FOR: 121,050,633 (99.6%)AGAINST: 398,401 (0.3%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “Election of Directors: David Hodgson” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

9. Election of Directors: Errol De Souza, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 468,014,051AGAINST: 17,919,666

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Errol De Souza, Ph.D.”): 468,014,051 for, 17,919,666 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 98% of the shares they voted on this item FOR (118,778,319 for, 2,670,715 against).

FOR 98%

FOR: 118,778,319 (97.8%)AGAINST: 2,670,715 (2.2%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “Election of Directors: Errol De Souza, Ph.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	0	1,773,729	0	Against
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	864,686	0	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Against
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

10. Election of Directors: Gregory Norden

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 472,819,630AGAINST: 13,114,794

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Gregory Norden”): 472,819,630 for, 13,114,794 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 99.3% of the shares they voted on this item FOR (120,644,730 for, 804,304 against).

FOR 99.3%

FOR: 120,644,730 (99.3%)AGAINST: 804,304 (0.7%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “Election of Directors: Gregory Norden” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	0	379,450	0	Against
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

11. ELECTION OF DIRECTORS: Henry Fernandez

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 467,493,605AGAINST: 18,441,850

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Henry Fernandez”): 467,493,605 for, 18,441,850 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 97% of the shares they voted on this item FOR (118,243,354 for, 3,205,680 against).

FOR 97%

FOR: 118,243,354 (97.3%)AGAINST: 3,205,680 (2.6%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “ELECTION OF DIRECTORS: Henry Fernandez” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,541,059	0	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	0	1,773,729	0	Against
Waddell & Reed	1,098,573	0	0	For
Advisor Managed Portfolios	950,000	47,944	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	561,708	302,978	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	755,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	534,568	0	0	For
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	31,485	391,821	0	Against
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

12. Election of Directors: Pablo Legorreta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 469,574,048AGAINST: 16,360,957

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Pablo Legorreta”): 469,574,048 for, 16,360,957 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 99.9% of the shares they voted on this item FOR (121,388,771 for, 263 against).

FOR 99.9%

FOR: 121,388,771 (100.0%)AGAINST: 263 (0.0%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “Election of Directors: Pablo Legorreta” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	695,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

13. Election of Directors: Ted Love , M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 457,219,827AGAINST: 28,488,315

ROYALTY PHARMA PLC’s own tally for this item (“Elect Director: Ted Love, M.D.”): 457,219,827 for, 28,488,315 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 98 asset managers below cast 98% of the shares they voted on this item FOR (119,317,839 for, 2,071,195 against).

FOR 98%

FOR: 119,317,839 (98.3%)AGAINST: 2,071,195 (1.7%)ABSTAIN: 45,346 (0.0%)

Largest asset managers voting on “Election of Directors: Ted Love , M.D.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	38,139,554	0	0	For
Fidelity	33,129,635	0	0	For
Morgan Stanley	11,535,322	5,737	0	For
Putnam	7,017,976	0	0	For
BlackRock	5,728,038	0	0	For
JPMorgan	4,785,936	0	0	For
Transamerica	2,890,819	0	0	For
Brighthouse	1,856,012	0	16,248	For
Charles Schwab	1,773,729	0	0	For
Waddell & Reed	0	1,098,573	0	Against
Advisor Managed Portfolios	997,944	0	0	For
TIAA	949,883	0	0	For
First Trust	927,223	0	0	For
Jackson National	864,686	0	0	For
JANUS INVESTMENT FUND	793,944	0	0	For
MUTUAL FUND SERIES TRUST	695,563	0	0	For
Eaton Vance	689,870	0	0	For
State Street	0	534,568	0	Against
HOMESTEAD FUNDS INC	483,484	0	0	For
Victory Capital	454,919	0	0	For
Aberdeen	451,065	0	0	For
Principal	423,306	0	0	For
RBB Fund Trust	379,450	0	0	For
AB EQUITY INCOME FUND INC	366,869	0	0	For
BAILLIE GIFFORD FUNDS	362,925	0	0	For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

14. Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports for the fiscal year ended December 31, 2023.

OTHER

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 97 asset managers below cast 100% of the shares they voted on this item FOR (121,474,765 for, 0 against).

FOR: 121,474,765 (100.0%)ABSTAIN: 16,248 (0.0%)

Largest asset managers voting on “Approve receipt of our U.K. audited annual report and accounts and related directors' and auditor's reports fo” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

15. Authorize the Board to allot shares without rights of pre- emption (special resolution).

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 455,564,249AGAINST: 30,278,595

ROYALTY PHARMA PLC’s own tally for this item (“Proposal 10. To authorize the Board of Directors to allot shares without rights of pre-emption:”): 455,564,249 for, 30,278,595 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 97 asset managers below cast 98% of the shares they voted on this item FOR (119,525,855 for, 1,965,158 against).

FOR 98%

FOR: 119,525,855 (98.4%)AGAINST: 1,965,158 (1.6%)

Largest asset managers voting on “Authorize the Board to allot shares without rights of pre- emption (special resolution).” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Vanguard	36,727,871	1,411,683	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	0	362,925	Against

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

16. Authorize the Board to allot shares.

CAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 97 asset managers below cast 99.9% of the shares they voted on this item FOR (121,449,478 for, 41,535 against).

FOR: 121,449,478 (100.0%)AGAINST: 41,535 (0.0%)

Largest asset managers voting on “Authorize the Board to allot shares.” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Against	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 97 asset managers. See all 97 in the interactive database.

17. Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next general meeting at which the U.K. annual report and accounts are presented to shareholders.

AUDIT-RELATED

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 96 asset managers below cast 99.9% of the shares they voted on this item FOR (121,458,896 for, 12,998 against).

FOR: 121,458,896 (100.0%)AGAINST: 12,998 (0.0%)ABSTAIN: 16,248 (0.0%)

Largest asset managers voting on “Re-appoint Ernst & Young as our U.K. statutory auditor, to hold office until the conclusion of the next genera” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	38,139,554	0	For
Fidelity	33,129,635	0	For
Morgan Stanley	11,541,059	0	For
Putnam	7,017,976	0	For
BlackRock	5,728,038	0	For
JPMorgan	4,785,936	0	For
Transamerica	2,890,819	0	For
Brighthouse	1,856,012	16,248	For
Charles Schwab	1,773,729	0	For
Waddell & Reed	1,098,573	0	For
Advisor Managed Portfolios	997,944	0	For
TIAA	949,883	0	For
First Trust	927,223	0	For
Jackson National	864,686	0	For
JANUS INVESTMENT FUND	793,944	0	For
MUTUAL FUND SERIES TRUST	755,563	0	For
Eaton Vance	689,870	0	For
State Street	534,568	0	For
HOMESTEAD FUNDS INC	483,484	0	For
Victory Capital	454,919	0	For
Aberdeen	451,065	0	For
Principal	423,306	0	For
RBB Fund Trust	379,450	0	For
AB EQUITY INCOME FUND INC	366,869	0	For
BAILLIE GIFFORD FUNDS	362,925	0	For

Showing the 25 largest of 96 asset managers. See all 96 in the interactive database.

18. Approve Remuneration Policy

COMPENSATION

100% fund support · no official result

FOR 98%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (103,125 for, 0 against).

FOR: 103,125 (97.8%)ABSTAIN: 2,289 (2.2%)

Largest asset managers voting on “Approve Remuneration Policy” at ROYALTY PHARMA PLC, 2023-2024
Asset manager	For	Abstain	Vote
Regime de rentes du Mouvement Desjardins	95,359	0	For
OSSIAM	6,688	0	For
Symmetry Panoramic Trust	1,078	2,289	Abstain

Largest ROYALTY PHARMA PLC shareholders voting in 2023-2024

Ranked by the number of ROYALTY PHARMA PLC shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 448,623,000 shares outstanding at the time of that meeting.

Top ROYALTY PHARMA PLC shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	Fidelity	14.35%
2	Morgan Stanley	10.42%
3	Vanguard	8.73%
4	BlackRock	4.49%
5	VIKING GLOBAL INVESTORS LP	2.57%
6	JPMorgan	2.57%
7	ADAGE CAPITAL PARTNERS GP, L.L.C.	2.41%
8	Swedbank Robur Fonder AB	1.87%
9	Putnam	1.82%
10	State Street	1.78%

Reported ROYALTY PHARMA PLC ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ROYALTY PHARMA PLC beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Continuing US Investors Partnership	32.34%	DEF14A
GISEV Trustees Limited	9.73%	DEF14A
Morgan Stanley	9.17%	DEF14A
FMR LLC	7.04%	DEF14A
FMR (Fidelity)	6.24%	13F
BlackRock	5.84%	13F
Vanguard Group	2.44%	13F
M. Germano Giuliani	2.30%	DEF14A
State Street	2.03%	13F
Geode Capital	1.46%	13F

Percentages above are of 448,623,000 shares outstanding, as reported by ROYALTY PHARMA PLC on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROYALTY PHARMA PLC’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ROYALTY PHARMA PLC's shareholder meeting held 2024-06-06, in the 2023-2024 proxy season, 405 asset managers reported how they voted in their SEC Form N-PX filings, covering 7,362 separate fund positions. Their filings are grouped here into 18 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve executive compensation. — FOR was 92% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ROYALTY PHARMA PLC's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).

ROYALTY PHARMA PLC proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.